Research analysts at Royal Bank Of Canada assumed coverage on shares of Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) in a research note issued to investors on Monday. The firm set an “outperform” rating and a $45.00 price target on the stock. Royal Bank Of Canada’s price objective indicates a potential upside of 117.39% from the stock’s current price.
ATTO has been the subject of a number of other research reports. Leerink Partners began coverage on Attovia Therapeutics in a research note on Monday. They issued an “outperform” rating and a $52.00 price target for the company. Morgan Stanley started coverage on Attovia Therapeutics in a research note on Monday. They set an “overweight” rating and a $39.00 target price on the stock. Finally, Citigroup began coverage on Attovia Therapeutics in a research note on Monday. They issued a “buy” rating and a $30.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $41.50.
Attovia Therapeutics Price Performance
Insider Transactions at Attovia Therapeutics
In other Attovia Therapeutics news, major shareholder Redmile Group, Llc purchased 200,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, with a total value of $3,400,000.00. Following the acquisition, the insider owned 982,854 shares in the company, valued at approximately $16,708,518. The trade was a 25.55% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Life Sciences Xi L.P. Frazier acquired 588,235 shares of the stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the purchase, the insider directly owned 6,154,213 shares in the company, valued at approximately $104,621,621. The trade was a 10.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 2,740,587 shares of company stock worth $47,269,979.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Attovia Therapeutics stock. BlackRock Inc. grew its position in Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 164,358 shares of the company’s stock after buying an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.
Attovia Therapeutics Company Profile
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Featured Stories
- Five stocks we like better than Attovia Therapeutics
- Palo Alto’s Rally Has One Big Problem Ahead of Earnings
- These 5 ETFs Have Raked in Cash This Year—What Do They All Have in Common?
- DLocal Is Testing the Breakout Level That Could Change Its Stock Story
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
Receive News & Ratings for Attovia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
